Cardiac amyloidosis, a condition resulting from abnormal protein deposits in heart tissue, is a diverse disease that can be challenging to diagnose, often necessitating specialized expertise and testing. The disease is categorized based on the specific protein involved, with the primary subtypes being transthyretin amyloidosis (ATTR cardiac amyloidosis), caused by the misfolding of the transthyretin protein, and a less common form called light chain amyloidosis (AL cardiac amyloidosis), caused by the buildup of immunoglobulin light chains. Now, an AI-powered platform can detect cardiac amyloidosis by analyzing echocardiograms and using just one commonly acquired ultrasound view of the heart.

The platform, EchoGo Amyloidosis, from Ultromics (Oxford, UK) utilizes AI technology to address the unmet need for early diagnosis of amyloidosis patients, who might otherwise remain undiagnosed until the disease has progressed, delaying treatment and negatively affecting patient outcomes. Developed in collaboration with multiple leading clinical partners, EchoGo Amyloidosis is designed as a module within Ultromics' EchoGo Platform and has received FDA Breakthrough Device Status. This FDA Breakthrough Device Designation represents a significant advancement for amyloidosis patients, who face a bleak five-year mortality rate of 44%-65% after diagnosis if the condition is not detected early enough.

"Receiving a breakthrough designation for EchoGo Amyloidosis, emphasizes the importance of this innovation," said Dr Ross Upton, CEO and Founder of Ultromics. "This is our second breakthrough designation and brings us one step closer to achieving our goal of providing earlier and more accurate diagnosis for this debilitating, underdiagnosed disease. We are excited to continue working with our partners to bring this technology to market and help improve outcomes for patients." 

http://www.gzjiayumed.com/en/index.asp